ArticleCancers2021
Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Survival disparities in HER2-low versus HER2-positive breast cancer: a systematic review of progression-free survival and overall survival.Frontiers in oncology · 2026Pooled it
- Influence of HER2-low and HER2-zero status on pathologic complete response and survival in triple-negative breast cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.ESMO open · 2023Pooled it
- Clinicopathologic characteristics and prognostic significance of HER2-low expression in patients with early breast cancer: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Emerging role of human epidermal growth factor 2-low status in the prognosis and management of triple-negative breast cancer: a narrative review.Translational cancer research · 2026Review
- Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?Cancers · 2026Review
- Comparison of Stromal Tumor-Infiltrating Lymphocyte (sTIL) Levels and Clinicopathological Features in Neoadjuvant-Naive HER2-Low and HER2-Negative Primary Breast Cancers.Medicina (Kaunas, Lithuania) · 2026Article
- Molecular characteristics and prognosis of triple negative breast cancer stratified by HER2 status.Chinese medical journal · 2026Article
- Exploring the spectrum of HER2 in non-metastatic triple negative breast cancer: from HER2-Null to HER2-low, including HER2-ultralow status.Virchows Archiv : an international journal of pathology · 2026Article
- Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.NPJ breast cancer · 2026Article
- A SHAP-interpretable XGBoost model: MRI-based intratumoral perfusion heterogeneity predicts HER2-zero, -low, and -positive ternary expression status in breast cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Inflammatory indexes as prognostic biomarkers in advanced triple negative breast cancer patients.Frontiers in oncology · 2026Article
- HER2 expression in breast cancer: evidence gaps and challenges.NPJ precision oncology · 2025Review
- Clinical characteristics and prognostic impact of HER2-ultralow breast cancer and tumor-infiltrating lymphocytes (TILs).BMC cancer · 2025Article
- Differences in Sentinel lymph node biopsy outcomes and prognosis between HER2-low and HER2-zero breast cancer.BMC cancer · 2025Article
- Redefining therapeutic landscapes: clinicopathological insights into low and ultra-low HER2 expression in male breast cancer.Diagnostic pathology · 2025Article
- Prognostic difference between early breast cancer patients with HER2 low and HER2 zero status.NPJ breast cancer · 2025Article
- Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies.NPJ breast cancer · 2025Article
- Prognostic Value of Trop-2 Expression in Nonmetastatic Triple-Negative Breast Cancer and Correlation With Emerging Biomarkers.Cancer medicine · 2025Article
- Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy.Breast cancer research and treatment · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
HER2-low breast cancer (i.e., HER 1+ or 2+, without gene amplification) is an emerging subtype for which very few data are available, especially within the triple-negative breast cancer (TNBC) group. Our aim was to evaluate HER2 expression and its prognostic value in a large retrospective series of patients with non-metastatic TNBC (median age: 57.7 years; range: 28.5-98.6). Among the 296 TNBC samples, 83.8% were HER2 0, 13.5% were HER2 1+, and 2.7% were HER2 2+ (HercepTest
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.